The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF™-100A system

Scott G Turner1*, Thomas Gergel1, Hueizhi Wu1, Michel Lacroix2 and Steven A Toms1

Abstract

The NovoTTF™-100A system is a portable device that delivers intermediate frequency alternating electric fields (TTFields, tumor treating fields) through transducer arrays arranged on the scalp. An ongoing trial is assessing its efficacy for newly diagnosed glioblastoma multiforme (GBM) and it has been FDA-approved for recurrent GBM. The fields are believed to interfere with formation of the mitotic spindle as well as to affect polar molecules at telophase, thus preventing cell division. The position of the four arrays is unique to each patient and optimized based on the patient’s imaging. We present three patients with GBM in whom the fields were adjusted at recurrence and the effects of each adjustment. We believe there may be a higher risk of treatment failure on the edges of the field where the field strength may be lower.

The first patient underwent subtotal resection, radiotherapy with temozolomide (TMZ), and then began NovoTTF Therapy with metronomic TMZ. She had good control for nine months; however, new bifrontal lesions developed, and her fields were adjusted with a subsequent radiographic response. Over the next five months, her tumor burden increased and death was preceded by a right insular recurrence.

A second patient underwent two resections followed by radiotherapy/TMZ and NovoTTF Therapy/TMZ. Six months later, two new distal lesions were noted, and he underwent further resection with adjustment of his fields. He remained stable over the subsequent year on NovoTTF Therapy and bevacizumab.

A third patient on NovoTTF Therapy/TMZ remained stable for two years but developed a small, slow growing enhancing lesion, which was resected, and his fields were adjusted accordingly. Interestingly, the pathology showed giant cell GBM with multiple syncitial-type cells.

Based on these observations, we believe that field strength may play a role in ‘out of field’ recurrences and that either the presence of a certain field strength may select for cells that are of a different size or that tumor cells may change size to avoid the effects of the TTFields.

**Keywords:** glioblastoma, tumor treating fields, cytotoxic, NovoTTF therapy, NovoTTF-100A System

Background

Glioblastoma multiforme (GBM) remains a fatal disease that affects more than 10,000 people in the United States each year [1]. Standard therapy currently consists of surgical resection, when possible, followed by radio- and chemotherapy. In 2005, Stupp et al. [2] demonstrated a significant improvement in progression-free survival at 6 months (PFS-6) and overall survival (OS) when temozolomide, an alkylating agent, was given during radiotherapy and for six months following radiation. More recently, bevacizumab, a monoclonal antibody against VEGF, has proven effective in treating patients with recurrent GBM [3]. Much interest exists regarding treatment options following progression on bevacizumab, one of which is the NovoTTF-100A system, which was FDA-approved in 2011 for adult patients with recurrent GBM following surgery and chemotherapy [4]. This modality utilizes a novel mechanism to target tumor cells with minimal local side effects.

Living cells contain many polar molecules that exert and respond to electric fields. Low frequency (<1 kHz) fields induce membrane depolarization, as seen in nerve
and muscle cells, whereas fields in the MHz range generate heat and are used in radiofrequency ablation and diathermy [5]. Low- to moderate-frequency fields (kHz to MHz) were thought to be biologically inert, but have been shown to cause cell rotation [6] and alignment of microscopic particles [7]. Kirson et al. determined that intermediate-frequency alternating fields exert these effects on tumor cells in vitro [8]. Cells become polarized during mitosis, and dividing cells tend to orient along the direction of an externally applied field. In addition, field intensity is increased at the cleavage furrow, which draws polar intracellular particles toward the furrow, which interferes with cytokinesis. At an intracellular level, assembly and disassembly of microtubules are disrupted in the presence of these fields due to changes in alignment of tubulin dimers that may prevent polymerization.

The device used with Novo TTF Therapy delivers electric fields alternating in direction through transducer arrays arranged on the scalp (Figure 1). Field strength, direction, and electrode position are important to optimize during treatment. Kirson et al. examined the effects of TTF on several human and animal tumor types in vitro and found that cell proliferation slowed during exposure to the fields and that the effect was dependent on the field frequency. The 200-kHz fields were the most cytotoxic to rat glioma (F-98) cells. When glioma cells were implanted intracranially into Fischer rats and treated with 200 kHz fields, it was found that fields applied in multiple directions are optimal for cytotoxicity since cells divide along random planes [9]. In our patients, as per the instructions for use, we use four arrays that are positioned on the scalp based on the patient’s imaging; these arrays deliver alternating fields along two planes in order to maximize delivery of the electric field to the tumor. By taking into account the different impedances of bone, skin, brain and CSF, Kirson et al. used computer modeling to demonstrate the distribution of field intensity within the brain [9]. Each patient’s magnetic resonance imaging (MRI) is used to individualize therapy to maximize delivery of the TTField to the region of the tumor, while other regions of the brain receive fewer volts per centimeter. More recently, the NovoTAL system has been developed for investigators to calculate the optimal placement of the electrodes on the scalp based on each of their patient’s imaging. We present three patients in whom the field location was adjusted after recurrence to better treat the new lesion based on updated imaging and the results of these adjustments.

**Case presentation**

**Case 1**

A 39-year-old woman who presented after a new-onset seizure was found to have a left parietal GBM (genetics not available) (Figure 2a). She underwent subtotal resection followed by radiotherapy with daily temozolomide (TMZ), and then NovoTTF Therapy with metronomic TMZ. After 3 months, her MRI showed progression near her initial resection site, and temozolomide was replaced by bevacizumab (BEV), with NovoTTF Therapy continuing. Nine months later, she had local recurrence in addition to bifrontal enhancing lesions (Figure 2b), and her TTFields were adjusted. Over the next five months, her multifocal tumor burden increased, and death was preceded by a right insular recurrence.

**Case 2**

A 41-year-old man presented after a week of intermittent headaches and was found to have a left frontal enhancing mass (Figure 3a). A gross total resection was performed and the pathology showed GBM with primitive neuroectodermal tumor (PNET) component (MGMT promoter unmethylated, EGFR not amplified, 1p/19q co-deletion negative). Surgery was followed by radiotherapy and daily TMZ and then NovoTTF therapy/metronomic TMZ. Six months later, a distal lesion were noted (Figure 3b), and he underwent further resection with adjustment of his fields. In order to address the PNET component if his tumor, and because a combination of ifosfamide, carboplatin, etoposide (ICE) has been shown to be effective against this tumor type [10], his chemotherapy was changed to bevacizumab with ICE (ifosfamide, carboplatin, etoposide) × six cycles. He continued on bevacizumab with NovoTTF therapy for over a year until he developed leptomeningeal disease and passed away in July 2013.

**Case 3**

A 45-year-old man presented with headaches and was found to have a right frontal GBM (MGMT promoter unmethylated, EGFR not amplified, 1p/19q codeletion status unknown) (Figure 4a), for which he had a gross total

![Figure 1 The NovoTTF-100A system.](http://www.wjso.com/content/12/1/162)
resection followed by radiation and daily TMZ and then metronomic TMZ with NovoTTF therapy. He remained neurologically intact with no radiographic evidence of recurrence for 22 months. A surveillance MRI revealed a small enhancing lesion in the left parietal lobe (Figure 4b), which was resected, and his fields were adjusted accordingly. The histology of the recurrent lesion showed multiple giant syncytial-type cells, and he has remained in good health over the subsequent nine months.

**Conclusions**

Given its poor prognosis, new therapies to treat GBM are desperately needed. The NovoTTF-100A System offers a treatment modality with minimal local side effects and no known systemic side effects, whose efficacy is comparable to other chemotherapy regimens [4]. In fact, combining chemotherapy with NovoTTF therapy may improve efficacy without added toxicity [11]. In order to optimize this response, the field strength and orientation must be taken into account; the positioning of the electrodes is based upon the patient’s MRI in order to optimize delivery of the field to the tumor.

Our three cases demonstrate that, when a tumor progresses locally, adjustment of the fields may lead to a better response; however, multifocal disease is difficult to optimally treat despite this adjustment, as seen in
our first patient. NovoTTF therapy failure leading to remote recurrence in the second two patients may have been due to lower field strength at these distal sites based upon the position of the electrodes; as the field was optimized in one location, the strength may have been lowered elsewhere below a threshold where newly seeded tumor cells were able to divide.

Following resection of the recurrent lesion in our third patient, we discovered that the cells had a ‘giant-cell’ morphology, leading us to hypothesize that giant cells avoided the toxicity of the TTFields or that existing cells adopted this giant cell phenotype, which may require different parameters to achieve cytotoxicity. Indeed, Kirson et al. [8] demonstrated that the optimal frequency for cytotoxicity in vitro differed in various tumor cell types and that optimal TTField frequency is inversely related to cell size [9]. Alternately, because this patient’s recurrence was distant from the original tumor site, the potentially decreased field strength may have also contributed to the recurrence, as we hypothesized for our other patients.

In addition to differences in TTFields strength within the brain, other factors may be associated with distant recurrence including radiation field strength and genetic profile. Brandes et al. [12] found that, in 79 patients with recurrent GBM treated with radiation plus daily TMZ followed by metronomic TMZ, distant recurrence (outside the radiation field) occurred in 21.5% of patients, while recurrence within or at the radiotherapy margin occurred in 85% of patients with MGMT unmethylated promoters and 57.9% of patients with MGMT methylated promoters. Why distant recurrence should be associated with MGMT promoter methylation is not known but may be due to changes in cell motility patterns or the fact that the combination of radiation and temozolomide act synergistically on cells with MGMT promoter methylation, thus reducing the likelihood of local recurrence. All three patients presented here had recurrence outside their initial radiation treatment fields, and though genetics are not available for our first patient, the second two patients had unmethylated MGMT promoters and would therefore be thought less likely to recur distally, according to the findings described by Brandes et al.

Treatment with anti-angiogenic agents should also be taken into account when considering distal GBM recurrence. Bevacizumab has been shown to induce a more invasive phenotype in vitro and in vivo, perhaps by up-regulating expression of matrix metalloproteinases [13]. In addition, clinical studies [14,15] have found that treatment with bevacizumab is associated with an increased incidence of distal recurrence. This may be due to genetic alterations that effect a more invasive phenotype, allowing cells to migrate along normal blood vessels or within the extracellular matrix in order to escape a hypoxic microenvironment [16]. The recurrences described in the first two patients presented here should therefore be considered in light of their treatment with bevacizumab. Further study is clearly warranted in order to better understand the
subcellular effects produced by the TTFields, allowing us to tailor them to specific tumor cell sizes and types.

Consent
Written informed consent was obtained from the patients for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Abbreviations
BEV: bevacizumab; EGFR: epidermal growth factor; GBM: glioblastoma multiforme; kHz: kilohertz; MGMT: methylguanine methyltransferase; MHz: megahertz; MRI: magnetic resonance imaging; OS: overall survival; PFS: progression-free survival at 6 months; PNET: primitive neuroectodermal tumor; TMZ: temozolomide; TTFields: tumor-treating fields.

Competing interests
Dr. Steven A. Toms has consulting agreements with Medtronics and Novocure.

Authors’ contributions
SGT drafted the manuscript. All authors read and approved the final manuscript.

Acknowledgements
The authors would like to thank Lynn Belles, Angela Whitmire, and Michelle Wilkus for their assistance with data collection and excellent patient care.

Author details
1Geisinger Medical Center, 17822 Danville, PA, USA. 2Geisinger Wyoming Valley, 18702 Wilkes-Barre, PA, USA.

Received: 28 February 2014 Accepted: 11 May 2014 Published: 22 May 2014

References
1. Dolecek TA, Proppe JM, Stroup NE, Kruchko C: CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro-Oncol 2012, 14(Suppl 1):v1–v49.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwig SK, Gorlia T, Allegro A, Lacombe D, Cairncross JG, Eisenhauer E, Machtay M, Blomquist C, Adjei AA, Denissenko MF, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwig SK, Gorlia T, Allegro A, Lacombe D, Cairncross JG, Eisenhauer E, Machtay M, Blomquist C, Adjei AA, Denissenko MF: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:977–986.
3. Cohen MH, Shen YL, Keeegan P, Pazdur R: FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 2009, 14:1131–1138.
4. Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann B, Dibaly V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunscher C, Rafter J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smirca M, Chin L, Kostorn H, Hofer S, et al: NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 2012, 48:192–220.
5. Chou CR: Radiofrequency hyperthermia in Cancer Therapy. In The Biomedical Engineering Handbook. Edited by Bronzino JD. Boca Raton, FL: CRC Press, Inc; 1995:1425–1430.
6. Zimmerman U, Venken J, Pilwat G: Rotation of cells in an alternating electric field: the occurrence of a resonance frequency. Z Naturforsch C 1981, 36:173–177.
7. Takahsima S, Schwab HP: Alignment of microscopic particles in electric fields and its biological implications. Physiol Biochem Fluids Membr 1985, 47:513–518.
8. Kirson ED, Guvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, Schatzberger R, Palti Y: Disruption of cancer cell replication by alternating electric fields. Cancer Res 2004, 64:3288–3295.
9. Kirson ED, Dibaly V, Tovaray F, Vymazal J, Soustiel JF, Itzhaki A, Mordechovich D, Steinberg-Shapira S, Guvich Z, Schneiderman R, Wasserman Y, Salzberg M, Ryfel B, Goldsher D, Dekel E, Palti Y: Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A 2007, 104:10152–10157.
10. Kumar R, Reddy SJ, Wani AA, Pal L: Primary spinal primitive neuroectodermal tumor: case series and review of the literature. Pediatr Neurosurg 2007, 43:1–6.
11. Kirson ED, Schneiderman RS, Dibaly V, Tovaray F, Vymazal J, Itzhaki A, Mordechovich D, Guvich Z, Shmueli E, Goldsher D, Wasserman Y, Palti Y: Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Med Phys 2009, 9:1.
12. Brandes AA, Tosoni A, Franceschi E, Sotti G, Frezza A, Amistà P, Morandi L, Spagnolli F, Ermano M: Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. J Clin Oncol 2009, 27:1275–1279.
13. Lucio-Eteroivic AK, Pao Y, de Groot JF:Mediators of glioblastoma resistance and invasion during antiangiogenic endothelial growth factor therapy. Clin Cancer Res 2009, 15:4589–4599.
14. Narayana A, Hummakkat SD, Medabalini P, Golfinos J, Parker E, Knoepf E, Zagoag D, Eagan P, Gruber D, Gruber ML: Change in pattern of relapse after antiangiogenic therapy in high-grade glioma. Int J Radiat Oncol Biol Phys 2012, 82:77–82.
15. Zuniga RM, Torcuato R, Jain R, Anderson J, Doyle T, Ellika S, Schultz L, Mikielens T: Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 2009, 91:329–336.
16. Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Met EG: Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol 2005, 7:134–153.

Cite this article as: Turner et al. The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF-100A system. World Journal of Surgical Oncology 2014 12:162.